Cardio Diagnostics Holdings, Inc. CDIO
Last close
1.69
2026-10-23
Market cap
$5.0M
2026-06-30 share count
52-week range
0.97 - 7.91
Valuation FY2025 figures against the last close
P/S337.4x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-3.71
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $14.8K | $34.9K | $17.1K | $950 | $901 | — |
| R&D | $641.2K | $228.0K | $145.2K | $40.4K | $31.5K | — |
| SG&A | $5.0M | $6.9M | $6.9M | $4.4M | $470.6K | — |
| Total operating expenses | $6.5M | $8.4M | $7.3M | $4.5M | $621.3K | — |
| Operating income | -$6.5M | -$8.4M | -$7.2M | -$4.5M | -$620.4K | — |
| Interest expense | $14.8K | $18.6K | $6.7M | — | — | — |
| Pre-tax income | -$6.5M | -$8.4M | -$8.4M | -$4.7M | -$620.4K | — |
| Income tax | — | — | — | $0 | $0 | — |
| Net income | -$6.5M | -$8.4M | -$8.4M | -$4.7M | -$620.4K | — |
| EPS, basic | -3.71 | -9.35 | -0.66 | -1.51 | -0.53 | — |
| EPS, diluted | -3.71 | -9.35 | -0.66 | -1.51 | -0.53 | — |
| Shares, diluted (wtd. avg.) | 1.8M | 896,424 | 12.7M | 3.1M | 1.2M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $0 | $0 | $1.3M | $4.1M | $512.8K | $237.1K |
| Receivables | $8.1K | $18.6K | $253.0K | $0 | $901 | — |
| Total current assets | $5.9M | $8.8M | $2.8M | $5.9M | $803.5K | — |
| Property, plant and equipment | $700.1K | $672.9K | $571.9K | — | — | — |
| Other intangibles | — | $5.3K | $21.3K | $37.3K | $53.3K | — |
| Total assets | $7.8M | $10.6M | $4.5M | $6.2M | $1.1M | — |
| Accounts payable | $97.4K | $87.7K | $243.2K | $1.1M | $33.9K | — |
| Total current liabilities | $604.8K | $631.7K | $841.1K | $1.9M | $124.4K | — |
| Total liabilities | $793.1K | $1.1M | $1.5M | $1.9M | $33.9K | — |
| Retained earnings | -$29.2M | -$22.8M | -$14.4M | -$6.0M | -$1.3M | — |
| Total equity | $7.0M | $9.6M | $3.0M | $4.3M | $1.1M | $60.4K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$5.7M | -$5.0M | -$5.7M | -$5.1M | -$585.3K | — |
| Depreciation and amortisation | $160.1K | $113.8K | $3.8K | $0 | — | — |
| Stock-based compensation | $110.2K | $2.6M | $1.3M | $0 | $60.0K | — |
| Capital expenditure | $187.3K | $214.8K | $575.7K | — | — | — |
| Investing cash flow | -$419.3K | -$404.2K | -$794.3K | -$368.0K | -$364.0K | — |
| Financing cash flow | $3.4M | $11.9M | $3.6M | $9.1M | $1.2M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001553350-26-000023.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $901 | $950 | $17.1K | $34.9K | $14.8K |
| Gross profit | — | — | — | — | — | — |
| Net income | — | -$620.4K | -$4.7M | -$8.4M | -$8.4M | -$6.5M |
Recent filings and events
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Regulation FD disclosure Item 7.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Regulation FD disclosure Item 7.01
- Annual report filed Form 10-K
- Regulation FD disclosure Item 7.01
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Shareholder vote Item 5.07
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2835
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| IDXX | IDEXX LABORATORIES INC /DE | $44.15B | 42.8x | 10.4% |
| LNTH | Lantheus Holdings, Inc. | $6.51B | 29.3x | 0.5% |
| NEOG | NEOGEN CORP | $2.66B | — | -2.7% |
| CLDX | Celldex Therapeutics, Inc. | $2.30B | — | -78.0% |
| NTLA | Intellia Therapeutics, Inc. | $1.57B | — | 16.9% |
| QDEL | QuidelOrtho Corp | $941.5M | — | -1.9% |
| ACHV | ACHIEVE LIFE SCIENCES, INC. | $667.8M | — | — |
| MYGN | MYRIAD GENETICS INC | $556.7M | — | -1.6% |